Medical Communications
Merck & Co agrees to buy biotech firm Afferent for upfront $500 million in cash
June 10, 2016 Medical Communications, Sales and Marketing Afferent Pharmaceuticals, Financial, M&A, MA, Merck & Co
Novartis presents strong results in rare blood disorder trials
June 10, 2016 Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder
Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma
June 10, 2016 Medical Communications, Research and Development Janssen, Phase III trials, drug trial, immunotherapy, multiple myeloma
Nice says Bayer’s Eylea not recommended as first-line treatment in draft recommendation
June 10, 2016 Medical Communications, Research and Development Bayer, Eylea, NICE, recommendation, regulation
FDA targets online illegal prescription drugs sellers
June 10, 2016 Medical Communications, Sales and Marketing FDA, Ireland, illegal drug sales
India-based Cipla gets new chief financial officer
June 8, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cipla, Dr Reddy's, cfo, dr reddys
Drug Pricing: Cancer drugs cost the most in US, but most unaffordable in India, China – Study
June 7, 2016 Medical Communications, Research and Development, Sales and Marketing ASCO, Drug pricing, oncology, social
The Pharmafocus ASCO round-up
June 7, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, Pharmafocus
Novo Nordisk presents positive long-term results for Saxenda
June 3, 2016 Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss
Shire completes Baxalta takeover
June 3, 2016 Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales
Eisai partners with Novartis in renal cell carcinoma collaboration
June 3, 2016 Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate
Bayer, Orion to start Phase III trials for prostate cancer drug
June 3, 2016 Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research
New FDA expanded access guidelines spell trouble for Sarepta
June 2, 2016 Medical Communications, Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, Eteplirsen, FDA, compassionate grounds, sarepta
Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia
June 2, 2016 Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia
Nice rejects Janssen’s Imbruvica in draft guidance
June 1, 2016 Medical Communications, Research and Development
Latest content
MedPharm appoints Jason Mieding as chief operating officer
Coriolis Pharma appoints Teun van der Heide as CEO
The evidence bar impacting UK medical cannabis access
